ALSENLITE: Senolytics for Alzheimer's Disease
ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer's Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women of age 55 years and older at the time of enrollment
- Clinical diagnosis of symptomatic probable AD (MMSE 26 to 15 or Short Test of Mental Status 31 to 15 inclusive and/or Clinical Dementia Rating Scale/CDR = 0.5 to 2, inclusive)
- Not on cholinesterase inhibitors or memantine; or if on cholinesterase inhibitors and/or memantine, on a stable dose for at least three months
- Body Mass Index (BMI) within range of 19 - 50 kg/ m2
- Participants must be accompanied by a LAR designated to sign informed consent and to provide study partner reported outcomes at all visits
- Participants must have no plans to travel over the ~3 months between Visits 3 and 14 that interfere with study visits
- Tau positivity by brain PET imaging
- Adequate blood counts i.e. platelets > 50,000 per microliter; HB > 9/dL, and ANC > 1000 per microliter
- Availability and consent from a LAR.
Exclusion Criteria:
- Unwilling or unable to give informed consent
- Pregnancy
- QTc > 450 msec on baseline ECG
- MRI contraindications
- Presence of uncontrolled psychiatric disorder (as per clinical judgment)
- Presence of uncontrolled systemic lupus erythematosus (as per clinical judgment)
- Substance or alcohol abuse (current alcohol use > 3 alcoholic beverage/day or > 21 per week and as per clinical judgment)
- Hearing, vision, or motor deficits despite corrective devices (as per clinical judgment)
- Myocardial infarction, angina, stroke, or transient ischemic attack in the past 6 months
- Chronic heart failure (as per clinical judgment)
- Neurologic, musculoskeletal, or other condition that limits subject's ability to complete study physical assessments (as per clinical judgment)
- Positive SARS-CoV-2 test within 30 days prior to enrollment
- AST/ALT > 2.5x upper limit normal
- Presence of significant liver disease with total bilirubin > 2X upper limit or as per clinical judgment
- Inability to tolerate oral medication (as per clinical judgment)
- Abnormality in any of the screening laboratory studies (see section 6.21.2) or as per clinical judgment
- Malabsorption (as per clinical judgment)
- Known human immunodeficiency virus infection (as per clinical judgment)
- Known active hepatitis B or C infection
- Invasive fungal or viral infection (as per clinical judgment)
- Known hypersensitivity or allergy to D or Q
- Uncontrolled pleural/pericardial effusions or ascites (as per clinical judgment)
- New/active invasive cancer except non-melanoma skin cancers
- Inability to tolerate oral medications (as per clinical judgment)
- Currently taking AND unable to safely hold any of the medications listed in Appendix 1 during the days IP is administered and for 36 hours after IP administration.
- Uncontrolled diabetes (defined as HbA1c > 7% or as per clinical judgment).
- Gastric bypass/reduction
- Crohn's disease
- Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase or ESR) (as per clinical judgment)
- eGFR < 10 ml/ min/ 1.73 m2
- Creatinine clearance < 60 mL/min/1.73 m2
- Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.)
- On antiplatelet agents (e.g., full dose Aspirin, Clopidogrel etc.). Baby aspirin (81 mg), if absolutely necessary from cardiac perspective, will be allowed
- Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial
Involvement of special vulnerable populations: We will not involve special vulnerable populations, such as fetuses, neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations except for patients with dementia. Therefore, availability and consent from a LAR is an inclusion criterion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dasatinib plus Quercetin Treatment Goup
Subjects with MCI or Alzheimer's disease will take Dasatinib and Quercetin by mouth at the same times for 2 days out of every 15 days for 6 cycles lasting for a total of 77 days (12 concurrent doses of each agent).
|
100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles
Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety and Tolerability
Time Frame: 11 weeks
|
Safety evaluations will be conducted including assessment for adverse events, compliance to the study drug regimen, physical examinations or assessments, vital signs, and laboratory assessments.
|
11 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Vijay K. Ramanan, MD, PhD, Mayo Clinic
Publications and helpful links
General Publications
- Guerrero A, De Strooper B, Arancibia-Carcamo IL. Cellular senescence at the crossroads of inflammation and Alzheimer's disease. Trends Neurosci. 2021 Sep;44(9):714-727. doi: 10.1016/j.tins.2021.06.007. Epub 2021 Aug 5.
- Andrews TD, Day GS, Irani SR, Kanekiyo T, Hickson LJ. Uremic Toxins, CKD, and Cognitive Dysfunction. J Am Soc Nephrol. 2025 Jun 1;36(6):1208-1226. doi: 10.1681/ASN.0000000675. Epub 2025 Feb 26.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Neurocognitive Disorders
- Cognition Disorders
- Dementia
- Tauopathies
- Neurodegenerative Diseases
- Cognitive Dysfunction
- Alzheimer Disease
- Sulfur Compounds
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Pyrans
- Thiazoles
- Azoles
- Pyrimidines
- Benzopyrans
- Flavonols
- Flavonoids
- Chromones
- Dasatinib
- Quercetin
Other Study ID Numbers
Other Study ID Numbers
- 19-003394
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.